| Literature DB >> 33315237 |
Hirofumi Uyama1,2, Masayo Takahashi1,2, Michiko Mandai1,2.
Abstract
Various advances have been made to treat retinal diseases, including new treatment strategies and innovations in surgical devices. However, treatment of degenerative retinal diseases, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), continues to pose a significant challenge. In this review, we focus on the use of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to treat retinal diseases by harnessing the ability of stem cells to differentiate into different body tissues. The retina is a tissue specialized for light sensing, and its degradation leads to vision loss. As part of the central nervous system, the retina has very low regenerative capability, and therefore treatment options are limited once it degenerates. Nevertheless, innovations in methods to induce the generation of retinal cells and tissues from ESCs/iPSCs enable the development of novel approaches for these irreversible diseases. Here we review some historical background and current clinical trials involving the use of stem cell-derived retinal pigment epithelial cells for AMD treatment and stem cell-derived retinal cells/tissues for RP therapy. Finally, we discuss our future vision of regenerative treatment for retinal diseases with a partial focus on our studies and introduce other interesting approaches for restoring vision. This article is protected by copyright. All rights reserved.Entities:
Keywords: Retinal Organoid; Retinal Pigment Epithelium; Stem cell; Transplantation; regenerative medicine
Year: 2020 PMID: 33315237 DOI: 10.1111/dgd.12704
Source DB: PubMed Journal: Dev Growth Differ ISSN: 0012-1592 Impact factor: 2.053